Summary

A sustainable improvement in functional capacity, symptoms, and quality of life was shown in patients with symptomatic chronic heart failure (HF) and iron deficiency (ID) who were treated with intravenous (IV) ferric carboxymaltose (FCM) throughout 1 year, and this treatment may reduce the risk of hospitalizations due to worsening HF. This article presents the results of A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency [CONFIRM-HF; Ponikowski P et al. Eur Heart J. 2014].